CCS
BLUE

Crosspoint Capital Strategies’s bluebird bio BLUE Stock Holding History

Crosspoint Capital Strategies’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,234
Closed -$3.04M – 130
2017
Q2 		$3.04M Buy
+2,234
New +$2.7M 2.66% 28
2015
Q2 		– Sell
-4
Closed -$7K – 611
2015
Q1 		$7K Buy
+4
New +$5.28K ﹤0.01% 408

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

Crosspoint Capital Strategies's BLUE Position: Q3 2017 in Review

Crosspoint Capital Strategies sold out of bluebird bio (BLUE) in Q3 2017, closing a stake of 2,234 shares — an estimated $3.04M sold.

Crosspoint Capital Strategies first reported a position in BLUE in Q1 2015 and held it in 2 quarters. The position peaked at $3.04M in Q2 2017. 243 funds tracked by Wall St. Rank hold BLUE as of Q3 2017.

  • Crosspoint Capital Strategies reported no remaining bluebird bio position as of Q3 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 2,234 bluebird bio shares in Q3 2017, an estimated $3.04M.
  • Crosspoint Capital Strategies first reported a position in bluebird bio in Q1 2015 and held it in 2 quarters.
  • Crosspoint Capital Strategies's bluebird bio position peaked at $3.04M in Q2 2017.
  • 243 funds tracked by Wall St. Rank held bluebird bio as of Q3 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2017, filed 6 Nov 2017.